ArticleMolecular therapy. Oncology2025
Identifying gene expression signatures of oncolytic virus response in patient-derived pancreatic ductal adenocarcinoma organoids.
Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering strategies to address immune and delivery barriers in pancreatic ductal adenocarcinoma: a barrier-matched translational framework.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma is among the deadliest cancers, with a poor prognosis. Viro-immunotherapy using oncolytic viruses represents a promising treatment. However, pancreatic ductal adenocarcinoma from different patients responds variably to these therapies, highlighting the need for predictive biomarkers. This study aimed to identify gene expression profiles that predict responses to oncolytic viruses. Patient-derived organoids (PDOs) from ten pancreatic ductal adenocarcinoma patients were evaluated for sensitivity to Newcastle disease virus (NDV), reovirus (RV), measles virus, and a gorilla-derived adenovirus. The sensitivity data revealed heterogeneous responses, with nine of ten PDOs being sensitive to at least one virus. The sensitivity of PDOs was correlated with their baseline transcriptome, resulting in gene expression profiles associated with sensitivity to each oncolytic virus. Gene Ontology analysis of the gene expression profiles revealed that intracellular aberrations, particularly those involved in embryonic development, were primary determinants of sensitivity. Additionally, for some oncolytic viruses (OVs), the gene expression profiles linked to sensitivity were associated with genes regulating cell cycle, metabolism, and cell proliferation. Screening tumors for these gene profiles may aid in selecting effective viral treatments for pancreatic ductal adenocarcinoma, providing the stepping stone toward personalized viro-immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.